Chemoembolization for Lung Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions
Lung MetastasesEndobronchial MetastasesPleural MetastasesMediastinal Metastases
Interventions
PROCEDURE

Chemoembolization

Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.

DRUG

Mitomycin C

Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.

DRUG

Lipiodol

Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.

DRUG

Embospheres

Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memoral Sloan Kettering Westchester (Consent only), Harrison

11725

Memorial Sloan Kettering Cancer Center @ Commack (Consent Only), Commack

07748

Memoral Sloan Kettering Monmouth (Consent only), Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04200417 - Chemoembolization for Lung Tumors | Biotech Hunter | Biotech Hunter